Clinical Trial: Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172347) titled 'Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo' on Sept. 08.

Brief Summary: This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Study Start Date: Oct. 20

Study Type: INTERVENTIONAL

Condition: Non-segmental Vitiligo

Intervention: DRUG: VC005 tablets

VC005 groups repeat administration for 52 weeks

DRUG: VC005 Tablets Placebo

VC005 Placebo groups repeat administration for 52 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Disclaimer: Curated by HT Syndication....